
Photo: Charkha, Janak Bhatta, CC BY-SA 4.0
UPSC Civil Services (Main) 2024 · GS Paper IV
UPSC Mains 2024 GS 4 · Q12: model answer
General Studies Paper IV: Ethics, Integrity and Aptitude · Case Studies.
Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means.
(a) What would you do in such a situation?
(b) Examine your options and consequences in the light of the ethical questions involved.
(c) How can data ethics and drug ethics save humanity at large in such a scenario?
Syllabus: Case Studies · Case studies
Research integrityInformed consentData ethicsIntellectual property
In an epidemic, speed saves lives, but a drug approved on manipulated data can cost many more. Dr Srinivasan is being pressed to hide negative outcomes, skip informed consent and use a rival's patented compound. Each shortcut violates research integrity, the law (the New Drugs and Clinical Trials Rules, 2019 and the Patents Act, 1970) and the first principle of medicine, do no harm.
1. Stakeholders and ethical issues
- Stakeholders: trial participants and future patients; the public facing the epidemic; the company and its shareholders; Dr Srinivasan and his team; the rival firm; regulators (CDSCO and ethics committees); doctors and the scientific community.
- Issues: falsification and selective reporting of data (scientific fraud); violation of autonomy and dignity by skipping consent; infringement of intellectual property; profit and first-mover advantage against patient safety; and loyalty to the employer against professional integrity.
2. (a) What I would do
- Refuse all three shortcuts firmly and record my objection in writing.
- Accelerate lawfully: adaptive and seamless trial designs, more trial sites, digital data capture, early meetings with CDSCO, and the accelerated approval route the 2019 Rules provide for serious diseases, unmet needs and emergencies.
- Respect intellectual property: seek a licence or collaboration with the rival firm, or develop our own compound; in a national emergency, compulsory licensing under the Patents Act is the government's lawful route.
- Brief management candidly: fraud invites rejection, recalls, lawsuits and criminal liability. Ranbaxy's 2013 guilty plea in the US over adulterated drugs and false statements to regulators, with a US$500 million settlement, shows the cost.
- Escalate if pressed: to the ethics committee and compliance, and as a last resort to the regulator; reset targets honestly.
3. (b) Options and consequences
| Option | Consequences | Ethical verdict |
|---|---|---|
| Adopt all shortcuts | Quick launch and profit; then unsafe drug, deaths, bans, prosecution | Violates honesty, autonomy and non-maleficence |
| Use only the rival's compound | Injunctions, damages, loss of reputation | Theft of others' work |
| Refuse and resign | Personal integrity kept | Project may continue with shortcuts |
| Refuse shortcuts, accelerate ethically, negotiate a licence (chosen) | Slower but safe, lasting approval and trust | Upholds integrity and the public good |
- Duty ethics (Kant): honesty and consent are duties that cannot be traded for speed; participants are never mere means.
- Consequences: short-term gains are far outweighed by long-term harm; thalidomide's birth defects and the withdrawal of Vioxx (2004) show how hidden risks become tragedies.
- Virtue: courage and honesty, with the prudence to find lawful ways to go faster; pure ends require pure means, as Gandhi taught.
4. (c) How data ethics and drug ethics protect humanity
- Trustworthy evidence: registering trials in advance (the Clinical Trials Registry-India, since 2007) and reporting negative results stop harmful drugs from reaching millions.
- Protection of participants: consent and ethics review under the Nuremberg Code (1947), the Declaration of Helsinki (1964) and the ICMR guidelines (2017) sustain public willingness to join trials, which is vital in pandemics.
- Safety after launch: the Pharmacovigilance Programme of India (2010) tracks adverse effects.
- Privacy: participants' health data must be kept confidential, as ethics guidelines and the DPDP Act, 2023 (being phased in) require.
- Equitable access: fair pricing, licensing and sharing, the spirit of the WHO Pandemic Agreement (2025), ensure that breakthroughs reach everyone.
Speed and ethics are not enemies. Science without integrity endangers the very humanity it seeks to save; Dr Srinivasan must choose the honest path and make it as fast as possible, because public trust is the most precious medicine in an epidemic.
The ₹149 All-in-One Pass opens the rest of the site for 12 months: UPSC Prelims GS Paper I and CSAT with explanations, practice quizzes and timed tests, UPSC CAPF and EPFO, the previous papers of every APPSC, TSPSC, police and SSC exam, every mock test series and the study books.
₹149 · valid for 12 months from the day you pay, on every exam · pay by UPI, card or net banking